<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1499286</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>General Commentary</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Xue</surname>
<given-names>Jihao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2847279"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yin</surname>
<given-names>Qijia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<xref ref-type="author-notes" rid="fn004">
<sup>&#x2021;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1501176"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Yanling</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1661807"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Neurosurgery, the Affiliated Hospital, Southwest Medical University</institution>, <addr-line>Luzhou, Sichuan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Urology or Nursing, Dazhou First People&#x2019;s Hospital</institution>, <addr-line>Dazhou, Sichuan</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>College of Nursing, Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Rehabilitation or Nursing, the Affiliated Hospital of Southwest Medical University</institution>, <addr-line>Luzhou, Sichuan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Abdulqadir J. Nashwan, Hamad Medical Corporation, Qatar</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Xiangming Mao, Southern Medical University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Yanling Li, <email xlink:href="mailto:liyanling27@swmu.edu.cn">liyanling27@swmu.edu.cn</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other" id="fn004">
<p>&#x2020;ORCID: Nadia Sabbah, <uri xlink:href="https://orcid.org/0009-0008-9380-6535">orcid.org/0009-0008-9380-6535</uri>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1499286</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>12</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Xue, Yin, Wang and Li</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Xue, Yin, Wang and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front Immunol" journal-id-type="nlm-ta" xlink:href="10.3389/fimmu.2023.1128151" ext-link-type="doi">
<bold>A Commentary on</bold>
<article-title>Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification</article-title> By Peng Z, Wang J, Tong S, Wu Y, Yi D and Xiang W (2023) <italic>Front. Immunol.</italic> 14:1128151. doi:&#xa0;<object-id>10.3389/fimmu.2023.1128151</object-id>
</related-article>
<kwd-group>
<kwd>proportional hazards (PH) assumption</kwd>
<kwd>cox regression</kwd>
<kwd>global test</kwd>
<kwd>glioma</kwd>
<kwd>nomogram</kwd>
</kwd-group>
<contract-num rid="cn001">82072780, 82372825</contract-num>
<contract-sponsor id="cn001">National Outstanding Youth Science Fund Project of National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/100014717</named-content>
</contract-sponsor>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="7"/>
<page-count count="3"/>
<word-count count="679"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>We read with great interest the recently reported work by Peng et&#xa0;al., entitled &#x201c;Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification&#x201d; (<xref ref-type="bibr" rid="B1">1</xref>). In this study, the authors conducted univariate and multivariate Cox regression analyses in combination with common clinicopathological characteristics and ultimately determined that PDCL3 acted as a potential prognostic biomarker of glioma. They subsequently established a nomogram in the TCGA cohort and confirmed that the nomogram had satisfactory prognostic efficiency for glioma. While we fully recognize the important contributions made by this study, we would like to highlight a few crucial aspects for further scrutiny and analysis. Firstly, it is essential to underscore that the application of Cox regression models necessitates the adherence to the proportional hazards (PH) assumption for the independent variables (<xref ref-type="bibr" rid="B2">2</xref>). This means that the hazard ratio associated with each independent variable must remain constant over time (<italic>p</italic> &gt; 0.05). Violation of this assumption can lead to inaccuracies and biases in the statistical inferences drawn from the model (<xref ref-type="bibr" rid="B3">3</xref>). In addition, to ensure that the Cox regression model complies with the PH assumption, it is important to conduct a GLOBAL test. A <italic>p</italic>-value greater than 0.05 in this test serves as a strong indicator that the model satisfies the PH assumption, thereby validating its appropriateness for statistical analysis (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>Similarly, we performed univariate and multivariate Cox regression analyses (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) on the relevant clinical parameters the same as those used by Peng et&#xa0;al. (<xref ref-type="bibr" rid="B1">1</xref>) from glioma patients in the TCGA cohort, and tested the PH assumption of multivariate Cox regression (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Subsequently, we constructed a nomogram (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>) based on multivariate Cox regression, and also plotted calibration curves (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) and ROC curves (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>). The results showed that Age, WHO grade, IDH status, PDCL3 expression levels and GLOBAL did not fulfill the PH hypothesis (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>), which may affect the credibility and accuracy of the predictive model proposed by Peng et&#xa0;al. (<xref ref-type="bibr" rid="B1">1</xref>) from a statistical perspective.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Construction and evaluation of the nomogram. <bold>(A)</bold> Multivariate Cox regression analyses in the TCGA cohort. <bold>(B)</bold> Nomogram based on age, WHO grade, IDH status, 1p/19q codeletion and PDCL3 expression. <bold>(C)</bold> Calibration curves showed the concordance between predicted and observed 1-, 3-, and 5-year OS. <bold>(D)</bold> ROC curve analyses of the nomogram in predicting 1-, 3-, and 5-year OS.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1499286-g001.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>PH assumption test to multivariate Cox regression.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Variable</th>
<th valign="top" align="center">Chi-Square Value</th>
<th valign="top" align="center">Degree of freedom</th>
<th valign="top" align="center">
<italic>P</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">Age</td>
<td valign="top" align="center">6.426</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">0.011</td>
</tr>
<tr>
<td valign="top" align="center">WHO grade</td>
<td valign="top" align="center">7.456</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">0.024</td>
</tr>
<tr>
<td valign="top" align="center">IDH status</td>
<td valign="top" align="center">25.304</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">4.9e-07</td>
</tr>
<tr>
<td valign="top" align="center">1p/19q codeletion</td>
<td valign="top" align="center">1.465</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">0.226</td>
</tr>
<tr>
<td valign="top" align="center">PDCL3</td>
<td valign="top" align="center">5.5687</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">0.018</td>
</tr>
<tr>
<td valign="top" align="center">GLOBAL</td>
<td valign="top" align="center">30.203</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">3.6e-05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>If the <italic>p</italic>-value in the GLOBAL test &gt; 0.05, it indicates that the multivariate Cox regression adheres to the PH assumption</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In light of the aforementioned considerations, it is imperative to adopt a more rigorous approach to evaluating the predictive capabilities of the model. Firstly, to ensure the robustness and validity of the Cox regression analysis, we propose the inclusion of interaction terms between covariates and time. This refinement enables the model to capture the potential time-varying effects of covariates on the hazard function, thereby addressing the potential violation of the PH assumption (<xref ref-type="bibr" rid="B5">5</xref>). Secondly, to further scrutinize the stability of the predictive outcomes, we suggest stratifying the dataset based on the covariates that fail to meet the PH criterion. Within each stratum, separate Cox regression analyses can be conducted, allowing for a more nuanced understanding of the covariate effects within specific subgroups (<xref ref-type="bibr" rid="B6">6</xref>). Lastly, we also advocate for the consideration of alternative survival analysis methodologies, particularly accelerated failure time model (<xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>Despite our efforts to remind researchers of the prerequisites for using multi-factor Cox regression and constructing nomograms, there are still many papers published that have overlooked the PH assumption in their research. This situation indicates that the rigorous validation of models remains a neglected but crucial aspect in scientific research.</p>
</body>
<back>
<sec id="s1" sec-type="author-contributions">
<title>Author contributions</title>
<p>JX: Writing &#x2013; review &amp; editing, Writing &#x2013; original draft. QY: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. MW: Writing &#x2013; review &amp; editing. YL: Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s2" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Natural Science Foundation of Southwest Medical University, Grant (No. 2023QN008 and 2023QN103).</p>
</sec>
<sec id="s3" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s4" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1128151</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1128151</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stensrud</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Hern&#xe1;n</surname> <given-names>MA</given-names>
</name>
</person-group>. <article-title>Why test for proportional hazards</article-title>? <source>Jama</source>. (<year>2020</year>) <volume>323</volume>:<page-range>1401&#x2013;2</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2020.1267</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Concato</surname> <given-names>J</given-names>
</name>
<name>
<surname>Feinstein</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Holford</surname> <given-names>TR</given-names>
</name>
</person-group>. <article-title>The risk of determining risk with multivariable models</article-title>. <source>Ann Intern Med</source>. (<year>1993</year>) <volume>118</volume>:<page-range>201&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7326/0003-4819-118-3-199302010-00009</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisher</surname> <given-names>LD</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>DY</given-names>
</name>
</person-group>. <article-title>Time-dependent covariates in the cox proportional-hazards regression model</article-title>. <source>Annu Rev Public Health</source>. (<year>1999</year>) <volume>20</volume>:<page-range>145&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev.publhealth.20.1.145</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leon</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Day</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>XS</given-names>
</name>
</person-group>. <article-title>If the ratio of hazards R(T)=&#x39b;e(T)/&#x39b;c(T) does not depend on time T then the proportional hazards assumption holds</article-title>. <source>J Thorac Oncol</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e116</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/JTO.0b013e3182a4081f</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLernon</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Giardiello</surname> <given-names>D</given-names>
</name>
<name>
<surname>Van Calster</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wynants</surname> <given-names>L</given-names>
</name>
<name>
<surname>van Geloven</surname> <given-names>N</given-names>
</name>
<name>
<surname>van Smeden</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Assessing performance and clinical usefulness in prediction models with survival outcomes: practical guidance for cox proportional hazards models</article-title>. <source>Ann Intern Med</source>. (<year>2023</year>) <volume>176</volume>:<page-range>105&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7326/m22-0844</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayehmiri</surname> <given-names>K</given-names>
</name>
<name>
<surname>Eshraghian</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Mohammad</surname> <given-names>K</given-names>
</name>
<name>
<surname>Alimoghaddam</surname> <given-names>K</given-names>
</name>
<name>
<surname>Foroushani</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Zeraati</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: cox proportional hazard versus accelerated failure time models</article-title>. <source>J Exp Clin Cancer Res</source>. (<year>2008</year>) <volume>27</volume>:<elocation-id>74</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1756-9966-27-74</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>